Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer

Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer

Background: Bone metastatic prostate cancer (BMPCa), despite the initial responsiveness to androgen deprivation therapy (ADT), inevitably becomes resistant. Recent clinical trials with upfront treatment of ADT combined with chemotherapy or novel hormonal therapies (NHTs) have extended overall patien...

Full description

Bibliographic Details
Main Authors: Arturo Araujo, Leah M. Cook, Jeremy S. Frieling, Winston Tan, John A. Copland, Manish Kohli, Shilpa Gupta, Jasreman Dhillon, Julio Pow-Sang, Conor C. Lynch, David Basanta
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
computational model
mathematical oncology
androgen therapy resistance
bone metastatic prostate cancer
personalized treatment
Online Access:https://www.mdpi.com/2072-6694/13/4/677

Internet

https://www.mdpi.com/2072-6694/13/4/677

Similar Items